Craig Slingluff
Craig Slingluff
Verified email at
Cited by
Cited by
Tumor and microenvironment evolution during immunotherapy with nivolumab
N Riaz, JJ Havel, V Makarov, A Desrichard, WJ Urba, JS Sims, FS Hodi, ...
Cell 171 (4), 934-949. e16, 2017
Potential regulatory function of human dendritic cells expressing indoleamine 2, 3-dioxygenase
DH Munn, MD Sharma, JR Lee, KG Jhaver, TS Johnson, DB Keskin, ...
Science 297 (5588), 1867-1870, 2002
Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines
AL Cox, J Skipper, Y Chen, RA Henderson, TL Darrow, J Shabanowitz, ...
Science 264 (5159), 716-719, 1994
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment
H Harlin, Y Meng, AC Peterson, Y Zha, M Tretiakova, C Slingluff, ...
Cancer research 69 (7), 3077-3085, 2009
Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma
G Erdag, JT Schaefer, ME Smolkin, DH Deacon, SM Shea, LT Dengel, ...
Cancer research 72 (5), 1070-1080, 2012
An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins.
JC Skipper, RC Hendrickson, PH Gulden, V Brichard, A Van Pel, Y Chen, ...
The Journal of experimental medicine 183 (2), 527-534, 1996
Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating …
CL Slingluff Jr, GR Petroni, GV Yamshchikov, DL Barnd, S Eastham, ...
Journal of Clinical Oncology 21 (21), 4016-4026, 2003
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
JS Weber, G Gibney, RJ Sullivan, JA Sosman, CL Slingluff, DP Lawrence, ...
The Lancet Oncology 17 (7), 943-955, 2016
The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?
CL Slingluff Jr
The Cancer Journal 17 (5), 343-350, 2011
Phase I Trial of a Melanoma Vaccine with gp100280–288 Peptide and Tetanus Helper Peptide in Adjuvant: Immunologic and Clinical Outcomes
CL Slingluff Jr, G Yamshchikov, P Neese, H Galavotti, S Eastham, ...
Clinical Cancer Research 7 (10), 3012-3024, 2001
The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens.
TL Darrow, CL Slingluff Jr, HF Seigler
Journal of immunology (Baltimore, Md.: 1950) 142 (9), 3329-3335, 1989
Impact of patient distance to radiation therapy on mastectomy use in early-stage breast cancer patients
AT Schroen, DR Brenin, MD Kelly, WA Knaus, CL Slingluff Jr
Journal of clinical oncology 23 (28), 7074-7080, 2005
Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by …
T Tuting, CC Wilson, DM Martin, YL Kasamon, J Rowles, DI Ma, ...
The Journal of Immunology 160 (3), 1139-1147, 1998
Terminal modifications inhibit proteolytic degradation of an immunogenic mart‐127–35 peptide: Implications for peptide vaccines
LH Brinckerhoff, VV Kalashnikov, LW Thompson, GV Yamshchikov, ...
International journal of cancer 83 (3), 326-334, 1999
Lethal" thin" malignant melanoma. Identifying patients at risk.
CL Slingluff Jr, RT Vollmer, DS Reintgen, HF Seigler
Annals of surgery 208 (2), 150, 1988
Surgical management of regional lymph nodes in patients with melanoma. Experience with 4682 patients.
CL Slingluff Jr, KR Stidham, WM Ricci, WE Stanley, HF Seigler
Annals of surgery 219 (2), 120, 1994
Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma
HL Kaufman, CE Ruby, T Hughes, CL Slingluff
Journal for immunotherapy of cancer 2 (1), 1-13, 2014
Anorectal melanoma: clinical characteristics and results of surgical management in twenty-four patients.
CL Slingluff Jr, RT Vollmer, HF Seigler
Surgery 107 (1), 1-9, 1990
Melan-A/MART-151–73 represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4+ T cells
HM Zarour, JM Kirkwood, LS Kierstead, W Herr, V Brusic, CL Slingluff Jr, ...
Proceedings of the National Academy of Sciences 97 (1), 400-405, 2000
Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling
JT Huntington, JM Shields, CJ Der, CA Wyatt, U Benbow, CL Slingluff, ...
Journal of Biological Chemistry 279 (32), 33168-33176, 2004
The system can't perform the operation now. Try again later.
Articles 1–20